Scienmag
DECEMBER 11, 2021
Tokyo, Japan – Researchers from Tokyo Metropolitan University have gained insights into the biochemistry of long-term memory. Studying fruit flies, they found that the Apterous (Ap) protein plays a crucial double role in retaining memories. Not only did it bind with the Chi cofactor to help maintain memories, but it also acted independently to regulate […].
ECRG Media's Clinical Research Podcast
DECEMBER 11, 2021
Senior CRA talks Remote Monitoring, Joys of Being a CRA - Full Interview Don't forget to Subscribe for new content! Merch: [link] Subscribe: [link] Email: eliteclinicalgroup@gmail.com Podcast: [link] [link] eliteclinicalgroup@gmail.com Watch: » Industry News: [link] All Videos: [link] Interview Recaps: [link] Glassdoor Reviews: [link] We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education Elite Clinical Res
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
DECEMBER 11, 2021
New York, NY (December 11, 2021) — Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe and well-tolerated and is associated with modest improvements in patients in a Phase 1b clinical trial. They shared their findings during an oral presentation at the American Society of Hematology annual […].
ECRG Media's Clinical Research Podcast
DECEMBER 11, 2021
Senior CRA talks Remote Monitoring, Joys of Being a CRA - Full Interview. Don't forget to Subscribe for new content! Merch: [link]. Subscribe: [link]. Email: eliteclinicalgroup@gmail.com. Podcast: [link] [link] eliteclinicalgroup@gmail.com Watch: » Industry News: [link] All Videos: [link] Interview Recaps: [link] Glassdoor Reviews: [link] We do: » Insider Interviews » Resume Reviews » Question and Answer » Discuss all things Clinical Research » News and Product Reviews » Education.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Scienmag
DECEMBER 11, 2021
ABSTRACTS 93, 739, 2 ATLANTA ? Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy. These results were reported at the 2021 American Society of Hematology (ASH) Annual Meeting. […].
BioTech 365
DECEMBER 11, 2021
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021) Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology … Continue reading →
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioTech 365
DECEMBER 11, 2021
Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH) Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the … Continue reading →
Scienmag
DECEMBER 11, 2021
Published today, one of the earliest, peer-reviewed studies looking into the Omicron variant of COVID-19 suggests that people previously infected with COVID, and those vaccinated, will have some, “stronger than basic” defence against this new strain of concern. However, the test tube (or ‘in-vitro’, scientifically) samples of Omicron examined in this new research do show […].
BioTech 365
DECEMBER 11, 2021
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting … Continue reading →
Scienmag
DECEMBER 11, 2021
Sophia-Antipolis – 11 December 2021: A novel artificial intelligence score provides a more accurate forecast of the likelihood of patients with suspected or known coronary artery disease dying within 10 years than established scores used by health professionals worldwide. The research is presented today at EuroEcho 2021, a scientific congress of the European Society of […].
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
BioTech 365
DECEMBER 11, 2021
IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society of Hematology Annual Meeting IGM Biosciences Presents Clinical Data from IGM-2323 in Patients with Advanced B Cell Malignancies at 2021 American Society … Continue reading →
Drug Patent Watch
DECEMBER 11, 2021
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Sweden. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Sweden? appeared first on DrugPatentWatch - Make Better Decisions.
BioTech 365
DECEMBER 11, 2021
Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology … Continue reading →
BioTech 365
DECEMBER 11, 2021
Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia Updated 48-week data from Phase III ASCEMBL trial consistent with … Continue reading →
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
BioTech 365
DECEMBER 11, 2021
Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia/Lymphoma Valemetostat Pivotal Data Shows Promising Response Rates in Patients with Adult T-Cell Leukemia/Lymphoma Oral presentation at ASH 2021 features positive phase 2 data in Japanese patients with … Continue reading →
BioTech 365
DECEMBER 11, 2021
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline – Precision BioSciences is Simultaneously Advancing Development of PBCAR0191, as Potential First-in-Class, and PBCAR19B as Potential … Continue reading →
BioTech 365
DECEMBER 11, 2021
MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study … Continue reading →
BioTech 365
DECEMBER 11, 2021
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021 Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021 – Bomedemstat continues to … Continue reading →
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
BioTech 365
DECEMBER 11, 2021
Samsung Bioepis’ SB12 Soliris® (Eculizumab) Biosimilar Demonstrates PK, PD Bioequivalence in Phase 1 Study Samsung Bioepis’ SB12 Soliris® (Eculizumab) Biosimilar Demonstrates PK, PD Bioequivalence in Phase 1 Study Phase 1 study demonstrated pharmacokinetics (PK) equivalence and comparable pharmacodynamic (PD), safety, … Continue reading →
BioTech 365
DECEMBER 11, 2021
Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 … Continue reading →
BioTech 365
DECEMBER 11, 2021
Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North Allarity Therapeutics Announces Shareholder Acceptance of Share Swap Offer and Initiates Delisting of the Company’s Shares from Nasdaq First North … Continue reading →
BioTech 365
DECEMBER 11, 2021
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic … Continue reading →
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
BioTech 365
DECEMBER 11, 2021
Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up Complete and overall response … Continue reading →
BioTech 365
DECEMBER 11, 2021
AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd American Society of Hematology Annual Meeting AlloVir Announces Positive Preliminary Data from the Ongoing Phase 2 Posoleucel Multi-Virus Prevention Study at the 63rd … Continue reading →
BioTech 365
DECEMBER 11, 2021
Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy … Continue reading →
BioTech 365
DECEMBER 11, 2021
Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas … Continue reading →
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
BioTech 365
DECEMBER 11, 2021
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing … Continue reading →
BioTech 365
DECEMBER 11, 2021
Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting Epizyme Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH … Continue reading →
BioTech 365
DECEMBER 11, 2021
Aleta Biotherapeutics Announces ALETA-001 Poster Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting Aleta Biotherapeutics Announces ALETA-001 Poster Presentation at the 63rd American Society of Hematology (ASH) Annual Meeting Pre-clinical results demonstrate durable response in CD-negative lymphoma … Continue reading →
BioTech 365
DECEMBER 11, 2021
Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease Forma Therapeutics’ Investigational Once-Daily Etavopivat Significantly Improved Anemia and Red Blood Cell Health in Patients with Sickle Cell Disease Updated etavopivat … Continue reading →
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
88 
Let's personalize your content